Erbitux (North America) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Erbitux (North America) General Information

Description

Portfolio of rights related to the pharmaceutical product Erbitux (cetuximab). The rights include, but are not limited to, full commercialization and manufacturing operational responsibilities. Erbitux is an epidermal growth factor receptor antagonist which provides treatments for gastrointestinal, colorectal, head and neck cancers.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Pharmaceuticals
Biotechnology
Corporate Office
  • 345 Park Avenue
  • New York, NY 10154
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Erbitux (North America) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Erbitux (North America)‘s full profile, request access.

Request a free trial

Erbitux (North America) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Erbitux (North America)‘s full profile, request access.

Request a free trial

Erbitux (North America) FAQs

  • Where is Erbitux (North America) headquartered?

    Erbitux (North America) is headquartered in New York, NY.

  • What industry is Erbitux (North America) in?

    Erbitux (North America)’s primary industry is Buildings and Property.

  • Is Erbitux (North America) a private or public company?

    Erbitux (North America) is a Private company.

  • What is Erbitux (North America)’s current revenue?

    The current revenue for Erbitux (North America) is 000000.

  • Who are Erbitux (North America)’s investors?

    Bristol-Myers Squibb has invested in Erbitux (North America).

  • When was Erbitux (North America) acquired?

    Erbitux (North America) was acquired on 16-Apr-2015.

  • Who acquired Erbitux (North America)?

    Erbitux (North America) was acquired by Eli Lilly and Company.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »